Literature DB >> 3412596

Alterations in receptors for thyrotropin-releasing hormone, serotonin, and acetylcholine in amyotrophic lateral sclerosis.

S Manaker1, S B Caine, A Winokur.   

Abstract

We utilized quantitative autoradiography to examine thyrotropin-releasing hormone (TRH) receptors, serotonin type 1A (5-HT1A) receptors, muscarinic cholinergic receptors, choline uptake sites, beta-adrenergic receptors, and norepinephrine uptake sites in discrete laminae of spinal cord from patients with amyotrophic lateral sclerosis (ALS) and non-neurologic controls. We found decreases of over 50% in the concentration of TRH receptors in lamina IX of cervical, thoracic, and lumbar spinal cord from ALS patients. Similar reductions were noted in concentrations of muscarinic cholinergic receptors in lamina IX of spinal cords from ALS patients. Significant increases of up to 140% in 5-HT1A receptor densities were noted in lamina IX of spinal cords from ALS patients. No differences were noted between the concentrations of beta-adrenergic receptors or norepinephrine uptake sites in patients with ALS and controls. These findings suggest that TRH and 5-HT may be involved in the pathophysiology of ALS, and act in a comodulatory role in the normal spinal cord.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3412596     DOI: 10.1212/wnl.38.9.1464

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Prolactin response to growth hormone-releasing hormone during chronic thyrotropin-releasing hormone infusion in the treatment of amyotrophic lateral sclerosis.

Authors:  P G Chiodini; R Attanasio; A Liuzzi; R Cozzi; P Orlandi; C De Palo; D Dallabonzana; F Girotti; D Testa
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

2.  Amyotrophic lateral sclerosis: thyroid and prolactin hormone changes in thyrotropin-releasing hormone therapy.

Authors:  D Testa; P G Chiodini; F Girotti; R Attanasio
Journal:  Ital J Neurol Sci       Date:  1990-12

3.  Effect of fluoxetine on disease progression in a mouse model of ALS.

Authors:  J E Koschnitzky; K A Quinlan; T J Lukas; E Kajtaz; E J Kocevar; W F Mayers; T Siddique; C J Heckman
Journal:  J Neurophysiol       Date:  2014-03-05       Impact factor: 2.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.